Cambridge, MA-based Exosome Diagnostics has named John Boyce its new CEO, taking over for Tom McLain. Boyce previously was the CEO of GnuBio, a DNA sequencing company that was sold to Bio-Rad for $110 million last year. Exosome, which is developing so-called liquid biopsies for prostate and lung cancer, is clearly thinking of a similar step—chairman Kapil Dhingra, in a statement, touted Boyce’s track record of “starting and growing companies to the IPO or acquisition stage.” Boyce is Exosome’s third CEO since its 2011 inception: McLain stepped in for founding CEO James McCullough in August 2014. Exosome said that McLain, meanwhile, will continue on with the company, but didn’t specify his role going forward.
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
View all posts by Ben Fidler